Annexon

Our mission is to develop novel disease modifying antibody therapies for neurodegenerative disorders by targeting the complement system.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Redwood City, CA, USA
  • Currency USD
  • Founded June 2011
  • Website annexon.biz

Company Summary

Annexon is discovering and developing novel disease modifying drugs for neurodegenerative disorders that represent unmet medical needs. We are building an antibody platform that targets various components of the complement system. Our most advanced programs target orphan auto immune neurological disorders from which we will expand in to Alzheimer's disease, glaucoma, traumatic brain injury, spinal cord injury, and multiple sclerosis.

Team

  • Arnon Rosenthal
    Co-Founder

    Arnon Rosenthal, PhD
    -25 years in biotechnology
    -16 years Genentech research executive
    -Founder, President, CSO, Rinat Neuroscience
    -5 drugs reached the clinic
    ~100 publications
    ~70 patents & applications

  • Ben Barres
    Co-Founder

    Ben Barres, MD, PhD
    -Chair,Dept. of Neurobiology, Stanford Medical School, & Professor of Neurobiology, Developmental Biology and Neurology
    -103 publications
    -13 patents
    -McKnight Scholar
    -Searle Scholar
    -HHMI Faculty Scholar
    -Salpeter Lifetime Achievement Award

  • John Wulf

Advisors

  • Wilson Sonsini
    Lawyer
    Unconfirmed

Previous Investors

  • Fidelity Ventures
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free